NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
Clinical Trials
164 trialsNCT04557059 2026-04-13
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT04513717 2026-04-03
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT03543189 2026-04-01
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT06244004 2026-03-30
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT04879940 2026-03-23
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06282588 2026-03-19
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT07477626 2026-03-17
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT07245745 2026-03-16
Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase NA Recruiting
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04422132 2026-02-27
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06650579 2026-02-24
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Phase 3 Recruiting
NCT06037863 2026-02-23
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
Mayo Clinic
Phase NA Active not recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03861676 2026-02-13
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT07202247 2026-02-04
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT04997018 2026-01-30
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT07364071 2026-01-27
SENTRY
University of California, San Diego
Phase 2 Not yet recruiting
NCT04134260 2026-01-14
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT06391034 2026-01-07
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT03987386 2025-11-12
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT06150417 2025-11-12
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT01368588 2025-10-28
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT03217747 2025-10-23
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT03678025 2025-09-11
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04319783 2025-08-21
DECREASE
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT03630666 2025-08-17
OLIGOPELVIS2
Institut Cancerologie de l'Ouest
Phase NA Active not recruiting
NCT07112781 2025-08-13
FAST-ONE
Branch Office of "Hadassah Medical Ltd"
Phase NA Recruiting
NCT04545957 2025-07-28
JUMP
Brigham and Women's Hospital
Phase NA Recruiting
NCT02177292 2025-07-01
SIB
Medical College of Wisconsin
Phase NA Active not recruiting
NCT05448547 2025-07-01
GrandP/SPCG19
The Hospital of Vestfold
Phase 3 Recruiting
NCT06625970 2025-06-26
PEACE 7
UNICANCER
Phase 3 Recruiting
NCT06992232 2025-05-28
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT04984343 2025-05-21
FORT
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT00328614 2025-05-16
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT01420250 2025-05-15
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT04302454 2025-04-04
ADOPT
University Medical Center Groningen
Phase 3 Active not recruiting
NCT04049747 2025-03-24
IP4-CHRONOS
Imperial College London
Phase NA Completed
NCT04298983 2025-03-19
RAD 1805
University of Alabama at Birmingham
Phase 2 Terminated
NCT06582446 2025-03-11
HypoElect
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT06855589 2025-03-04
PCS-XII
Charles LeMoyne Hospital
Phase 3 Not yet recruiting
NCT03763253 2025-02-07
IP2-ATLANTA
Imperial College London
Phase 2 Active not recruiting
NCT00223171 2025-01-27
PCS IV
Université de Sherbrooke
Phase 3 Active not recruiting